Delivery Order SPE2DB25D9320-SPE2DB25FWFCY
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a $8,622.72 firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract, which carries no set-aside designation, is set for ultimate completion by September 4, 2025, and represents a delivery order issued under DMS Pharmaceutical Group's substantial Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,311.35 by the Defense Logistics Agency (DLA) on July 31, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The delivery order carries an ultimate completion date of August 1, 2025, and was issued without set-aside designation. This award represents a single delivery order issued under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,311.35 by the Defense Logistics Agency on September 8, 2025, for the supply of Xtandi 40 mg capsules (quantity: 120). This firm fixed-price delivery order, which is scheduled for completion by September 9, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $499.99...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency on September 4, 2025, for the supply of Xtandi 40 mg capsules (120-count units) with a ceiling value of $17,245.40. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 5, 2025. This award carries no set-aside designation, demonstrating the company's competitive...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $43,113.50 by the Defense Logistics Agency on August 20, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of August 21, 2025, and no set-aside designation was used in the award. Performance will occur at the contractor's facility in Park...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,622.72 by the Defense Logistics Agency on August 25, 2025, for the supply of Xtandi 40 mg capsules (120-count). The contract carries no set-aside designation and is scheduled for completion by August 26, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,565.70 for Xtandi 40mg capsules (120 count) by the Defense Logistics Agency's Medical Supply Chain on September 13, 2025. This firm fixed-price delivery order carries no set-aside designation and is being performed at the awardee's Park Ridge location. The award represents a single delivery order under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $4,311.35 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on July 18, 2025, for 120 capsules of Xtandi 40 mg. The delivery order is not designated as a set-aside contract and carries an ultimate completion date of July 21, 2025. This award represents a single delivery transaction executed under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $17,245.40 by the Defense Logistics Agency on August 13, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The award carries no set-aside designation and is structured as a firm fixed-price delivery order with an ultimate completion date of August 14, 2025. This award is issued under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,311.35 by the Defense Logistics Agency on July 18, 2025, for the supply of Xtandi 40 mg capsules (120-count). The delivery order carries an ultimate completion date of July 21, 2025, and does not utilize a set-aside designation. This award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with...
- SPE2DB25D9320Indefinite Delivery Contract
- SPE2DB25D9320-SPE2DB25FWFCYDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,311.35 by the Defense Logistics Agency (DLA) on September 16, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract utilizes a firm fixed-price delivery order structure with an ultimate completion date of September 17, 2025. This award was made without a set-aside designation, allowing DMS Pharmaceutical Group to compete directly in the federal procurement market based on its established capabilities and competitive positioning. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. The IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products supporting medical supply needs across military health facilities. Xtandi, an oncology medication, represents the type of specialized pharmaceutical product that DMS Pharmaceutical Group routinely supplies to Department of Defense healthcare sites as part of its role as a critical supplier in the federal pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 9/16/25 |